# Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

> **NCT00269126** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 150 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** fluticasone propionate/salmeterol combination DISKUS
- **DRUG:** salmeterol xinafoate

## Key facts

- **NCT ID:** NCT00269126
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2013-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269126, "Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT00269126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*